2001, Licensing, Pharmaceuticals and Protein Expression

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2001

Licensing

Pharmaceuticals

Protein Expression

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

The Pharma Data

JANUARY 13, 2021

14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. Tonix Pharmaceuticals Holding Corp. GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. CHATHAM, N.J.,

Pharmaceuticals

Pharmaceuticals Small Molecule Vaccine Protein Expression

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Sara Majocchi, PhD, Discovery Program Leader, Light Chain Bioscience – Novimmune SA, on: ‘Bispecific antibody mediated, PD-L1-dependant, CD28 co-stimulation’.

Engineering

Engineering Therapies Protein Production Science

Drug Discovery Digest

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

What to expect from PEGS Europe 2023: Day 2

Stay Connected